Table 1 Clinicopathologic characteristics of FGFR2 translocation and non-translocation in ICCs.

From: Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas

No. of patients

FGFR2 translocation (N = 9)

FGFR2 non-translocation (N = 164)

p value

Average age (year)

57.00 (48–62)

61.27 (34–81)

0.054

Male/female

6/3

79/85

0.324

HBV infection (+/–)

5/4

45/119

0.123

Cholangitis (+/–)

7/2

123/41

1.000

Fatty liver (+/–)

2/7

29/135

0.664

Schistosome (+/–)

0/9

7/157

1.000

Tumor numbers (n)

3.25 (1–10)

2.11 (1–11)

0.467

Tumor maximum dimension (cm)

7.04 (2.8–11.5)

5.66 (0.5–16)

0.266

Gross classification

  

0.038a

MF type

9

110

 

Non-MF type

0

54

 

Histological classification

  

0.052

Pancreaticobiliary type

8

92

 

Others type

1

72

 

Differentiation (W/M/P/U)

0/5/4/0

4/75/82/3

0.893

G (0/1/2/3/4)

2/4/1/1/1

16/79/52/15/2

0.119

S (0/1/2/3/4)

4/2/2/1/0

31/63/45/8/17

0.287

T (I/II/III/IV)

5/4/0/0

56/64/35/9

0.310

Stage (I/II/III/IV)

5/3/0/1

51/46/26/41

0.288

OS (month)

28.25 (4–53)

45.10 (3–82)

0.984

DFS (month)

30.48 (4–53)

33.37 (1–82)

0.263

  1. G grade, M moderately differentiated, OS overall survival, P poorly differentiated, S stage, T tumor, U undifferentiated, W well differentiated.
  2. aStatistically significant.